anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hereditary breast/ovarian cancer syndrome is associated with mutations in tumor suppressor BRCA1 and BRCA2 genes. Products of these genes play an important role in the repair of DNA double-strand breaks. Mutations in BRCA1 and BRCA2 genes could impair DNA repair. In resting or G1 cells, where the de novo synthesis of DNA precursors is absent, the salvage pathway is the sole provider of deoxyribonucleotides to be used in DNA repair. For this process a sufficient supply of deoxynucleotides and activity of Thymidine Kinase 1 are essential. TK1 is an important component of adaptive response of cells to DNA damage. Mutations in genes directly engaged in the DNA repair process could lead to the accumulation of DNA damage and in turn cause an adaptive cell reaction manifesting as permanently increased Thymidine Kinase 1 activity.

A recently developed new high-sensitive assay DiviTum® allows to investigate the contribution of this enzyme to DNA repair processes and to make a comparison of Thymidine kinase 1 activity in women with normal and impared DNA repair system.
The present invention relates to an antidepressant, anti-anxiety, anti-stress, tension-relieving or stress-relieving composition containing a fermented perilla frutescens extract. In addition, the present invention relates to a fermented perilla frutescens extract-containing composition for preventing, ameliorating, or treating stress-related disorders, depression, or anxiety. In addition, the present invention relates to a fermented perilla frutescens extract-containing fiber or fragrance composition for relieving depression, anxiety, tension, or stress. In addition, the present invention relates to a method for treating depression or anxiety, the method comprising administering a fermented perilla frutescens extract to a patient suffering from a stress-related disorder, depression, or anxiety. A fermented perilla frutescens (Perilla frutescens Britton var. acuta Kud (Chajgi), or Perilla frutescens Britton var. crispa Decaisn (Jasoyeop)) extract according to the present invention significantly relieves stress compared to an unfermented perilla frutescens extract, and thus can be used as an antidepressant, anti-anxiety, tension-relieving or stress-relieving composition, and furthermore, can be effectively used in a composition or therapeutic method for preventing, ameliorating, or treating stress-related disorders, depression, and anxiety.
PURPOSE: To obtain a stable cleansing emulsion not having an irritating by using a self-emulsifiable composition based on a fatty alcohol as an emulsifying agent, and an acrylic copolymer as a gelling agent. CONSTITUTION: This oil-in-water cleansing emulsion having the appearance of a milk, comprises a self-emulsifiable composition based on a fatty alcohol as an emulsifying agent and an acrylic copolymer as a gelling agent, and has <=1 pa.s viscosity. This emulsion can be used for cleansing the skin, to the depth thereof, of the face and/or the body, has no irritating property, has a flowing property, and shows a good stability. The above acrylic copolymer is a cross-linked copolymer of a 3-6C monoethylenic acid or anhydride thereof and an acrylic acid ester. Especially the monoethylenic acid of formula I (R1 is H, a halogen, an alkyl, etc.), and the acrylic acid ester of formula II (R2 is H, methyl, etc.; R3 is an alkyl, etc.), are preferable. As the emulsifying agent, it is preferable to contain an alkylpolyoxide and a polyoxide in addition to the fatty alcohol.
Tricitrates oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion.
Adalimumab-adbm is intended for use under the guidance and supervision of a physician. A patient may self-inject Adalimumab-adbm or a caregiver may inject Adalimumab-adbm using either the Adalimumab-adbm Pen or prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

Adalimumab-adbm can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap while allowing it to reach room temperature. Carefully inspect the solution in the Adalimumab-adbm Pen or prefilled syringe for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. Adalimumab-adbm does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe. NOTE: Instruct patients sensitive to latex not to handle the needle cap of the Adalimumab-adbm 40 mg/0.8 mL and 40 mg/0.4 mL Pen or 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, and 10 mg/0.2 mL prefilled syringes because they contain natural rubber latex [see How Supplied/Storage and Handling (16)].

Instruct patients using the Adalimumab-adbm Pen or prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
Patients planning to receive radiation therapy to the head and neck/brain, thorax, abdomen, or pelvis will undergo imaging on the Halcyon 4.0 system. Patients will return for a minimum of 2 sessions over 9 weeks, with a cumulative total of 10 images being collected.
UNLABELLED: Our aim was to investigate the ability of an artificial intelligence (AI)-based algorithm to differentiate innocent murmurs from pathologic ones. An AI-based algorithm was developed using heart sound recordings collected from 1413 patients at the five university hospitals in Finland. The corresponding heart condition was verified using echocardiography. In the second phase of the study, patients referred to Helsinki New Children's Hospital due to a heart murmur were prospectively assessed with the algorithm, and then the results were compared with echocardiography findings. Ninety-eight children were included in this prospective study. The algorithm classified 72 (73%) of the heart sounds as normal and 26 (27%) as abnormal. Echocardiography was normal in 63 (64%) children and abnormal in 35 (36%). The algorithm recognized abnormal heart sounds in 24 of 35 children with abnormal echocardiography and normal heart sounds with normal echocardiography in 61 of 63 children. When the murmur was audible, the sensitivity and specificity of the algorithm were 83% (24/29) (confidence interval (CI) 64-94%) and 97% (59/61) (CI 89-100%), respectively.
CONCLUSION: The algorithm was able to distinguish murmurs associated with structural cardiac anomalies from innocent murmurs with good sensitivity and specificity. The algorithm was unable to identify heart defects that did not cause a murmur. Further research is needed on the use of the algorithm in screening for heart murmurs in primary health care.
WHAT IS KNOWN: • Innocent murmurs are common in children, while the incidence of moderate or severe congenital heart defects is low. Auscultation plays a significant role in assessing the need for further examinations of the murmur. The ability to differentiate innocent murmurs from those related to congenital heart defects requires clinical experience on the part of general practitioners. No AI-based auscultation algorithms have been systematically implemented in primary health care.
WHAT IS NEW: • We developed an AI-based algorithm using a large dataset of sound samples validated by echocardiography. The algorithm performed well in recognizing pathological and innocent murmurs in children from different age groups.
BACKGROUND: The role of epigenetics in cardiovascular diseases has paved the way for innovative therapeutic approaches. Investigating epigenetic changes using cell-free DNA (cfDNA) holds substantial promise beyond mere diagnostics, especially for heart-related conditions like acute myocardial infarction (AMI), where obtaining tissue samples is a challenge. This study explores the methylation patterns of cfDNA in AMI patients and compares them with genomic DNA (gDNA) from the same individuals, aiming to evaluate the effectiveness of cfDNA as a valuable resource for studying heart-related diseases.
METHODOLOGY: We generated global methylome profiles of cfDNA and gDNA from 25 AMI patients using EM-Seq. Tissue deconvolution analysis was performed to estimate tissue specificity based on the methylation patterns. Differentially methylated loci were identified and explored to understand AMI pathophysiology.
RESULTS: Comparative analysis of cfDNA and gDNA methylation patterns in AMI patients reveals cfDNA holds more significance than gDNA. Principal component analysis revealed distinct clusters for cfDNA and gDNA, indicating distinct methylome profiles. cfDNA originated from multiple sources, predominantly from neutrophils (~ 75%) and about 10% from the left atrium, highlighting cardiac-specific changes. In contrast, immune cells are the major source of gDNA, indicative of inflammatory responses. Gene set enrichment analysis (GSEA) associates cfDNA methylation patterns with pathways related to cardiac muscle contraction, inflammation, hypoxia, and lipid metabolism. The affected genes include G protein-coupled receptors (GHSR, FFAR2, HTR1A, and VIPR2) that are part of the cAMP signaling pathway.
CONCLUSION: Epigenetic changes in cfDNA are more specific to cardiac tissue compared to those in gDNA, providing better insights into the molecular mechanisms involved in AMI. Genes that are differentially methylated in cfDNA and regulate core pathways, such as cAMP signaling, could be targeted for clinical applications, including the development of effective biomarkers and therapeutic targets.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes derivatives of 5-(hydroxymethyl)-2-one of the formula (I)   where X means oxygen or sulfur atom or the group NR where R is hydrogen atom or normal or branched C 1 -C 4 -alkyl; R 1  means hydrogen atom or methyl-group; R 2  means: (i) the group R 3 O where R 3  is either hydrogen atom or benzyl-group possibly substituted with hydrogen atom or benzyl group possibly substituted with halogen atom or nitro- or methylenedioxy- -group or it means the group methoxyethyl, 4,4,4-trifluoro- -butyl, 4,4,4-trifluoro-3-hydroxybutyl or 4,4,4-trifluorobut- -2-enyl group; or (ii) the group -CH=CH-R 4  or -CH 2 -CH 2 -R 4  where R 4  means hydrogen atom or the group phenyl, 3,3,3-trifluoro-propyl or 3,3,3-trifluoro-2-hydroxypropyl in the form of enantiomers or diastereomers or mixture of these different forms including racemic mixtures. Invention describes also some methods of synthesis of proposed compounds, drug and pharmaceutical composition based on thereof. Invention can be used for preparing remedies used for treatment of patients with depressive states of any etiology. EFFECT: improved method of synthesis and preparing, valuable medicinal properties. 11 cl, 1 tbl, 17 ex
Cisplatin resistance is a major cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC). Long noncoding RNAs (lncRNAs) have emerged as key regulators of human cancers; however, their modes of action in HGSOC remain largely unknown. Here, we provide evidence to demonstrate that lncRNA Platinum sensitivity-related LncRNA from Ascites-Derived Exosomes (PLADE) transmitted by ascites exosomes enhance platinum sensitivity in HGSOC. PLADE exhibited significantly decreased expression in ascites exosomes and tumor tissues, as well as in the corresponding metastatic tumors from patients with HGSOC cisplatin-resistance. Moreover, HGSOC patients with higher PLADE expression levels exhibited longer progression-free survival. Gain- and loss-of-function studies have revealed that PLADE promotes cisplatin sensitivity by suppressing cell proliferation, migration and invasion, and enhancing apoptosis in vitro and in vivo. Furthermore, the functions of PLADE in increasing cisplatin sensitivity were proven to be transferred by exosomes to the cultured recipient cells and to the adjacent tumor tissues in mouse models. Mechanistically, PLADE binds to and downregulates heterogeneous nuclear ribonucleoprotein D (HNRNPD) by VHL-mediated ubiquitination, thus inducing an increased amount of RNA: DNA hybrids (R-loop) and DNA damage, consequently promoting cisplatin sensitivity in HGSOC. Collectively, these results shed light on the understanding of the vital roles of long noncoding RNAs in cancers.
The trend in IONM usage in the current literature, which may be a direct consequence of improved efficacy of the procedure, and the development of optimized treatment algorithm \[6\]. Nevertheless, it is well known that the use of somatosensory evoked potentials (SEPs) alone may be ineffective in detecting a motor tract deficit \[7, 8\]. As a result, various methods for monitoring the motor tract of the spinal cord have been developed. The most commonly used stimulation technique is transcranial electric stimulation (TES) of the primary motor cortex by corkscrew electrodes placed in the scalp, to produce myogenic motor evoked potential\[9\]. The combination of SEPs and TES-MEPs provides global monitoring coverage of spinal cord function \[10\]. Based on the available evidence, it is recommended that the use of multimodality neuromonitoring be considered in complex spine surgery where the spinal cord or nerve roots are deemed to be at risk \[11\].
This study is a single center, randomized controlled study of up to 30 subjects with metabolic heart failure with preserved ejection fraction (HFpEF) phenotype. The study is designed to compare the effects of KE versus an energy and volume matched placebo on maximal exercise performance measured by CPET. Eligible subjects will have a known diagnosis of HF or type 2 diabetes or metabolic syndrome or obesity and will be selected from a larger population being followed in the Heart Failure Clinic at the Ohio State University Wexner Medical Center. Enrolled subjects will be stratified by sex to ensure equal proportions of men and women in each group (KE and placebo) and then randomly assigned (1:1) to a group, before washing out and crossing over to the other group (KE or Placebo). Subjects will follow the intervention of twice daily consumption of the KE or placebo for a period of 6 weeks, followed by a 4 week washout. All subjects will then crossover to the other group (KE or placebo) for another 6 weeks of intervention. Primary data will be collected at baseline and at the end of the 6-week intervention for both groups. In addition, subjects will undergo daily monitoring of blood markers, blood pressure, heart rate, and overall health. All subjects will continue standard HF and diabetes therapies with adjustment in medications as needed.

Cardiopulmonary exercise testing (CPET) also known as Maximal oxygen consumption testing (VO2) will be used to assess exercise performance, and Cardiac Magnetic Resonance Imaging (CMR) to evaluate cardiac function, myocardial blood flow, and cardiac and vascular function. CMR will provide insightful data on the magnitude, timeline, and functional impact of nutritional ketosis on cardiovascular function in patients diagnosed with HFpEF.
Subjects will present to the clinical research unit in the morning (approximately 6:30 a.m.) of the dosing day. A urine pregnancy test will be performed to rule out pregnancy prior to administration of the tedizolid phosphate dose to female subjects. The subject's height, total body weight, and vital signs (heart rate, blood pressure, temperature, and respiratory rate) will be recorded. Subjects judged (by study physician) to be healthy enough to participate will proceed with the study procedures.

An 18-20 gauge intravenous peripheral catheter will be inserted into the antecubital vein or a vein in the fore-arm of the non-dominant arm for sequential blood sampling, and an initial predose blood sample (5 mL) will be collected. A minimum of 3-5 mL of blood is required per pharmacokinetic sampling time-point. Each blood collection tube will be pre-labeled with: 1.) study protocol number; 2.) subject study number; 3.) date of collection; 4.) time-point. A 0.9% Sodium Chloride infusion may be run through the peripheral line at 30 to 40 mL per hour to maintain catheter patency for the 12 hour sampling phase. Alternatively, a heparin lock technique will be utilized to maintain intravascular catheter patency.

A single-dose of tedizolid phosphate will be administered as an intravenous infusion (250 mL normal saline) over 1 hour (\~8:00 a.m.). The intravenous administration tubing will be flushed with 0.9% Sodium Chloride infusion at 250 mL per hour (to match the tedizolid phosphate rate of infusion) for 10 minutes to ensure complete dose delivery. Blood samples (5 mL) will be collected 0.5 (middle of infusion), 1 (end of infusion), 2, 4, 6, 8, 12, 24, 48, and 72 hours post dose in blood collection tubes. The plasma will be harvested (centrifugation at 4°C) within 60 minutes of collection and stored at -70°C as two aliquots until analysis. The intravascular catheter "dead-space" volume will be discarded prior to blood sample collection by withdrawing 1.5-2 mL from the catheter to ensure no unintentional sample dilution. The intravascular catheter will be removed after the 12 hour sample and the subject will be discharged from the research unit. The subject will return to the research unit for blood sample collection on a daily basis at the following points: 24 (Visit 3), 48 (Visit 4), and 72 hours (Visit 5) after the dose via a peripheral vein needle stick. The exact date and time of blood sample collection will be recorded on case report forms. Each blood sample tube will be inverted and made up-right 5 times to afford mixing of blood with the anticoagulant. Blood samples will be maintained on wet ice and centrifuged at 1200 g for 10 minutes at 4°C within 60 minutes of collection to yield approximately 2 mL of plasma per 5 mL blood collection. The plasma samples will be transferred from the -20°C freezer for storage at -70°C at the end of the sample collection period until analysis.
The investigators will conduct a quasi-experimental pilot study of 'Stick To It', a prevention intervention that uses gamification principles and mechanics. The intervention includes an online timer that reminds men to get tested, online quizzes, and peer recruitment; these activities are awarded with points redeemable for chances at prizes at participating clinics. The intervention was designed based on findings from interviews with health staff and focus groups with young MSM, and with input from a gamification consultant. The primary hypothesis is that the intervention will increase repeat HIV/STI testing among young MSM. The intervention will be implemented at two STI clinics in Oakland and Los Angeles, California in 2-week intervals for six months. The investigators will review medical records of exposed and unexposed young MSM attending the same STI clinics to compare uptake of quarterly HIV testing and self-reported behavior after six months.
To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
The invention relates to a pharmaceutical pre-formulation in the form of a solid, free-flowing dry extract of natural mixtures of conjugated equine estrogens. Suitable pre-formulations of the natural mixtures of conjugated equine estrogens are used for solid galenic forms e.g. tabletting. The conjugated estrogens are provided for further galenic processing in a form which ensures chemical stability of the hormones and which enables them to be processed advantageously into solid galenic forms, e.g. a tablet. The invention also relates to a method for the production of the pre-formulations in the form of a dry extract.
FIELD: medicine, pharmacy. SUBSTANCE: composition has isoniazide or phthivazide or pyrazinamide as an active component and accessory substances taken at amount from 8 to 20% of total mass. Corn or potato starch is used as binding agent taken at amount from 8 to 20% of the active component mass. Stearic acid or its derivative is used as lubricating agent taken at amount from 0.5 to 1.2% of the active component mass. Pharmaceutical composition is made as tablet. Composition corresponds to requirements for the pharmaceutical agent. EFFECT: increased stability of agent at storage. 5 cl, 5 ex
Cancer is a significant cause of death after cardiovascular disease. The genomic, epigenetic and environmental factors have been found to be the risk factor for the disease. The most important genes that develop cancer are oncogenes and tumor suppressor genes. Among oncogenes, KRAS has emerged as a significant player in the development of many cancers. Dysregulation of the RAS signaling pathway either on account of mutation in significant genes involved in the pathway or aberrant expression of different miRNAs targeting these genes including KRAS. The focus is also on the alterations in 3'UTR of the KRAS gene sequence as well as the changes in the miRNA encoding genes especially the one targeting the KRAS gene. Efforts are also being put in to target the dysregulated KRAS gene as a therapeutic approach to treat different cancers. However, there are some challenges like resistance to KRAS inhibitors that need to be addressed.
The present disclosure provides a nutritional composition, such as a preterm infant formula that includes a protein source comprising whey protein and hydrolyzed casein protein. The whey protein to hydrolyzed casein ratio may be from about 90:10 to about 50:50 by weight. The hydrolyzed casein may have a degree of hydrolysis of from about 20% to about 80%. Additionally, provided are methods for improved gastric emptying and improved digestibility in a target subject, such as a preterm infant. When administered, the nutritional compositions may promote intestinal transit and absorptive capacity. Consequently, better growth and development, especially neurological development of the target subject may be achieved.
The sample analysis system analyzes the sample. The panel design generates a sample preparation specification. The preparation instrument prepares the sample using the sample preparation specification to generate a prepared sample. The sample analyzer analyzes the prepared sample. The validator validates operation of the sample analysis system. The sample analysis system has a transfer station that controls movement of the probe relative to the reaction plate. A probe cleaning module is also disclosed.